Processa Pharmaceuticals
PCSA
18 hedge funds and large institutions have $350K invested in Processa Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 3 closing their positions.
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
0% more funds holding
Funds holding: 18 → 18 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
0.03% less ownership
Funds ownership: 5.67% → 5.63% (-0.03%)
49% less capital invested
Capital invested by funds: $691K → $350K (-$342K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$31.6K |
| 2 |
Walleye Capital
New York
|
+$20K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$17.6K |
| 4 |
HF
HRT Financial
New York
|
+$7.37K |
| 5 |
Renaissance Technologies
New York
|
+$3.21K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$44.2K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$14K |
| 3 |
VCA
Verdence Capital Advisors
Hunt Valley,
Maryland
|
-$9.96K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$6.42K |
| 5 |
VF
Virtu Financial
New York
|
-$5.67K |
PCSA Hedge Fund Activity: Q3 2023 in Review
18 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Processa Pharmaceuticals (PCSA) for Q3 2023, worth a combined $350K — down 49% from $691K a quarter earlier.
Fund positioning in PCSA was balanced in Q3 2023: 3 funds opened new positions, 3 closed out, 5 added to existing stakes and 4 trimmed.
The largest buyer was Geode Capital Management, adding an estimated $31.6K. The largest seller was Citadel Advisors, cutting an estimated $44.2K.
- 18 institutional investors held Processa Pharmaceuticals (PCSA) as of Q3 2023, unchanged from Q2 2023.
- Funds reported $350K of Processa Pharmaceuticals stock for Q3 2023, down 49% quarter-over-quarter.
- 3 funds opened new Processa Pharmaceuticals positions in Q3 2023 and 3 closed out, a net change of 0 holders.
- The largest Processa Pharmaceuticals buyer in Q3 2023 was Geode Capital Management, an estimated $31.6K added.
- The largest Processa Pharmaceuticals seller in Q3 2023 was Citadel Advisors, an estimated $44.2K sold.
Based on aggregated 13F filings for Q3 2023.